StockData
BridgeBio Pharma, Inc. logo

BridgeBio Pharma, Inc. (BBIO) stock

BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 3/30
$78.01+1.21 (+1.58%)

Close on Nov 18, 2026Market cap $15.20BP/E –Yield –

BridgeBio Pharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BridgeBio Pharma's free cash flow for the twelve months ending Sep 30, 2026 was -$369.81M. For fiscal 2025 it was -$447.01M. The highest annual figure on record is -$40.95M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$447.01M–
FY2024Dec 31, 2024-$521.66M–
FY2023Dec 31, 2023-$529.03M–
FY2022Dec 31, 2022-$424.32M–
FY2021Dec 31, 2021-$511.18M–
FY2020Dec 31, 2020-$407.23M–
FY2019Dec 31, 2019-$256.23M–
FY2018Dec 31, 2018-$138.82M–
FY2017Dec 31, 2017-$40.95M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$44.46M–
Q2 FY2026Jun 30, 2026-$71.54M–
Q1 FY2026Mar 31, 2026-$197.35M–
Q4 FY2025Dec 31, 2025-$56.45M–
Q3 FY2025Sep 30, 2025-$110.04M–
Q2 FY2025Jun 30, 2025-$81.28M-208.9%
Q1 FY2025Mar 31, 2025-$199.24M–
Q4 FY2024Dec 31, 2024-$195.37M–
Q3 FY2024Sep 30, 2024-$180.70M–
Q2 FY2024Jun 30, 2024$74.65M–
Q1 FY2024Mar 31, 2024-$220.23M–
Q4 FY2023Dec 31, 2023-$125.25M–
Q3 FY2023Sep 30, 2023-$145.66M–
Q2 FY2023Jun 30, 2023-$113.78M–
Q1 FY2023Mar 31, 2023-$144.33M–
Q4 FY2022Dec 31, 2022-$94.04M–
Q3 FY2022Sep 30, 2022-$135.92M–
Q2 FY2022Jun 30, 2022-$32.86M–
Q1 FY2022Mar 31, 2022-$161.49M–
Q4 FY2021Dec 31, 2021-$136.43M–
Q3 FY2021Sep 30, 2021-$128.02M–
Q2 FY2021Jun 30, 2021-$94.00M–
Q1 FY2021Mar 31, 2021-$152.73M–
Q4 FY2020Dec 31, 2020-$98.41M–
Q3 FY2020Sep 30, 2020-$132.23M–
Q2 FY2020Jun 30, 2020-$88.20M–
Q1 FY2020Mar 31, 2020-$88.40M–
Q4 FY2019Dec 31, 2019-$77.95M–
Q3 FY2019Sep 30, 2019-$50.38M–
Q2 FY2019Jun 30, 2019-$68.33M–
Q1 FY2019Mar 31, 2019-$59.57M–
Q4 FY2018Dec 31, 2018-$47.16M–

More BridgeBio Pharma figures

See a number that looks wrong?